Description
RTA is a synthetic multi-receptor peptide investigated for its interaction with glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor pathways. It is classified as a tri-agonist compound and is currently the subject of ongoing preclinical and laboratory-based research focused on receptor signaling and pathway characterization.
Due to its multi-receptor activity, RTA is of interest in studies examining complex endocrine signaling networks, ligand–receptor interactions, and downstream cellular signaling processes.
RTA is supplied strictly for laboratory research purposes only. This compound is not approved by the FDA for human or veterinary use. It is not intended for diagnosis, treatment, or administration in any form.
